Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A

Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study is a phase 2, interventional study registered as NCT05998122 by The First Hospital of Jilin University, with a registry enrolment figure of 45 participants, started 2023-09-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W. Conditions listed: Locally Advanced Rectal Cancer; Total Neoadjuvant Treatment; Anti-PD-1. Primary outcome: Complete response rate (CR). Colorectal eligibility wording from the registry: "Pathologically diagnosed rectal adenocarcinoma: differentiated into Grade 1-3, that is, high, medium, and poorly differentiated tubular adenocarcinoma; classified as pMMR/MSS". Sites: China. No results are recorded here; the registry entry is the source.